Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
5,015
Total Claims
$2.1M
Drug Cost
728
Beneficiaries
$2,833
Cost/Patient
Risk Score Breakdown 15/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
-57%
Opioid rate vs peers
0.6% vs 1.3% avg
-30%
Cost per patient vs peers
$2,833 vs $4,034 avg
+75%
Brand preference vs peers
16.4% vs 9.4% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
0.6%
Opioid Rate
28
Opioid Claims
$351
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 818 claims · $1.7M
Generic: 4,159 claims · $331K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Teriflunomide | 19 | $229K |
| Rimegepant Sulfate | 108 | $176K |
| Ubrogepant | 121 | $151K |
| Ofatumumab | 12 | $122K |
| Pimavanserin Tartrate | 24 | $120K |
| Galcanezumab-Gnlm | 113 | $105K |
| Carbidopa/Levodopa | 27 | $75K |
| Erenumab-Aooe | 77 | $72K |
| Fremanezumab-Vfrm | 45 | $50K |
| Lacosamide | 93 | $40K |
| Dalfampridine | 32 | $35K |
| Rasagiline Mesylate | 101 | $31K |
| Fremanezumab-Vfrm | 37 | $28K |
| Midazolam | 19 | $22K |
| Levetiracetam | 322 | $16K |
Prescribing Profile
70
Unique Drugs
15.0
Anomaly Score
Patient Profile
67
Avg Age
59%
Female
1.33
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About